Login / Signup
An LNP-CRISPR gene editing drug demonstrates efficacy and safety in patients with hereditary angioedema following in vivo administration.
Norbert Pardi
Zoltán Ivics
Published in:
The Journal of allergy and clinical immunology (2024)
Keyphrases
</>
genome editing
crispr cas
genome wide
angiotensin converting enzyme
adverse drug
emergency department
drug induced
angiotensin ii